INTRODUCTION
Clostridium difficile is a fastidious anaerobe that causes nosocomial antibiotic-associated colitis, ranging from mild to severe disease, including pseudo-membranous colitis and toxic megacolon with a potentially fatal outcome [1] . Even though the pathogenesis, diagnosis and prevention of C. difficile infection (CDI) have received particular attention in recent years, CDI still remains a leading cause of healthcare-associated diarrhea with a profound clinical as well as economic impact [2] .
Estimates of the financial burden of CDI have been estimated to be between $2,454 and $16,464 for every healthcare-acquired CDI case in the US [3] [4] [5] , £4,107 in the UK [6] , and €7,147 in Germany [7] . The length of hospital stay (LOS) has been identified as the main cost driver in most economic studies of CDI [3, 4, 6] , with patients suffering from nosocomial CDI staying on average between 3 and 26 days longer than patients without CDI [6] [7] [8] [9] . Furthermore, an increase in LOS due to more severe disease was observed in recent studies [10] . It has been suggested that this may be partly attributable to long turnaround times of assays and algorithms used to detect the presence of C. difficile in stool samples [11] . The cell culture cytotoxin neutralization assay (CCNA) and also toxigenic culture are historically considered to be the gold standard assays for C. difficile detection [12, 13] . However, CCNA usually takes around 48 h until results can be reported and it requires the ability to perform cell culture [12] . Recent developments in testing for CDI include commercial and in-house polymerase chain reaction (PCR), as well as glutamate dehydrogenase (GDH) enzyme-based tests.
GDH assays require 4-6 h from receipt until reportable results are available. GDH detects toxigenic as well as non-toxigenic strains and while it has been recommended as a screening tool in combination with other confirmative tests for GDH-positive samples [13, 14] , its sensitivity was reported to be less than optimal [6, 15] . Although the performance of PCR assays was found to exceed the clinical performance of GDH-based individual tests and algorithms [15] , in-house molecular assays require technical expertise and additional capital expenses.
Acquisition cost of commercially available kitbased PCR assays are considered to be higher compared to GDH or CCNA [16] , but it has been
proposed that increased sensitivity of PCR could ultimately lead to cost savings due to more accurate diagnosis and reduced repeat testing [15] . Faster turnaround time from testing to reporting may result in shorter LOS and decreased risk of transmission. The impact of molecular methods for C. difficile detection on duration of hospital stay compared to other assays and potential cost savings due to shorter hospital stays or fewer repeat samples has yet to be determined.
In a prospective trial carried out in two acute care hospitals in Swansea, UK, the clinical utility of the real-time PCR test Xpert Ò C.
difficile (Cepheid, Sunnyvale, CA, USA) was assessed in comparison to CCNA. Xpert C.
difficile was found to be easy to use, rapid (\1 h run time), clinically useful, sensitive, and reliable in CDI diagnosis [17] .
The aim of this cost comparison study was to assess the cost of C. difficile PCR and its impact on LOS for patients with suspicion of CDI in an acute hospital site compared to CCNA as the conventional diagnostic reference method. 
METHODS

Xpert C. difficile PCR Assay
Stool specimens were directly tested on the closed GeneXpert random access platform, allowing for an autonomous, fully integrated and automated molecular analysis where extraction, amplification, and identification take place successively in the same cartridge. The assay includes reagents for the detection of C. difficile toxin B, binary toxin, and tcd deletion nt117 as well as the sample processing control. Any Xpert C. difficile assay not yielding a result on the first attempt was repeated using a new cartridge. If no result was obtained upon retesting, the specimen was reported as unresolved and excluded from the study while patient management was decided upon according to clinical diagnosis and the routine CCNA result.
Cost Comparison
In order to assess potential cost savings or additional costs to the health care service due to the use of real-time PCR for detection of C. difficile in stool samples, the number of C.
difficile samples per year tested in the ABMUHB, number of repeat samples, ratio of positive to negative samples, LOS for the four study groups, and incremental testing costs were considered. A detailed description of all parameters included in the cost calculations can be found in Appendix 2 in the ESM. Based on micro-costing, testing cost per sample was £36.18 for PCR, £7.53 for CCNApositive, and £8.78 for CCNA-negative samples (Table 1) . Staff hands-on time from sample reception in the laboratory to reporting of the results was more than five times more for CCNA compared to PCR for negative samples and four times more for positive samples (Table 1) .
During the clinical study, 3.14% (33/1,051) of samples tested by PCR did not yield a result at the first attempt. Of these, 11 had to be excluded from analysis due to insufficient sample and 7 (all mucoid) samples produced errors at second attempt. Cost of these repeat samples was included in the overall PCR costing Mean cost savings of up to £2,292.62 per patient could therefore be achieved by routinely using PCR instead of CCNA (see Appendix 2 in the ESM for description of calculations). In order to investigate the robustness of the results, we recalculated cost savings after changing the values of key parameters (see Table 3 ). Since the LOS results exhibited large variance and the differences were not significant, potential cost savings or additional investments were calculated based on the 95% confidence interval of the LOS results. Cost saving results
were found not to be robust when subject to changes in duration of hospital stay of negative patients. All other parameter changes did not significantly alter the results (Table 3) . Changes in the quantity of samples processed per year did not have a significant effect on cost savings even though a small potential of economies of scale based on capital investment and staff training costs might be more significant for large laboratories with high sample turnover (Table 3) . Due to the lack of statistical significance and large range and variance in LOS data, the results of this study cannot definitely confirm that cost savings will be made by using PCR. However, a clear trend can
be observed when results are tested for robustness indicating a high potential for savings (Table 3) .
DISCUSSION
Fast and accurate laboratory results have been suggested to impact patient management and infection control measures [20] . The high sensitivity and specificity of PCR-based assays [7] , and 57.6 years [10] , compared to 75 years in our study, which may explain the longer LOS due to potentially higher incidence of co-morbidities.
The cost comparison discussed here only considers the cost of diagnostic tests and the change in duration of hospital stay observed in this study. This approach appears valid considering that cost of additional bed days has been identified as the main cost driver in CDI comprising up to 94% of the overall costs [21, 22] . However, it may underestimate potential additional cost savings due to cost reductions in antibiotic treatment and isolation days, as found by other studies [23, 24] . Rapid PCR testing has also been suggested to have the potential for cost savings for detection of methicillin-resistant Staphylococcus aureus [25] and sepsis [26] and to result in cost savings of $1,037 per patient in infants with fever and cerebrospinal fluid pleocytosis [27] . To our knowledge, this study is the first to publish an investigation of potential cost savings with a The potential cost savings identified in our study may be attributed to the faster turnaround time of PCR-based screening tests allowing for more efficient and accurate patient management, which eventually results in decreased average LOS of 4.88 days for CDI positive and 7.03 for negative patients. Forster et al. [8] suggested that calculating LOS differences based on the overall LOS, not treating C. difficile as a time-varying covariable, overestimates the effect of CDI on duration of hospital stay as LOS before CDI will be incorrectly attributed to C. difficile. Differences in LOS and LOS Sample for patients tested by PCR compared to patients tested by CCNA only differed by less than half a day in our study, suggesting that the decreased LOS for patients tested by PCR can primarily be attributed to the impact of the diagnostic test.
GDH/toxin EIA-based assays also have shorter turnaround times and test costs are lower when compared to PCR. However, GDH and toxin EIAs have repeatedly been reported to have a lower sensitivity compared to PCR and CCNA [11, 15, [28] [29] [30] despite being widely used and recommended as a two-step algorithm [13, 14] .
Our clinical study found that, when compared to clinical diagnosis, 16.2% of true CDIs were GDH negative and a further 59.7% of GDH positive, clinically confirmed CDIs were negative in toxin EIA [17] . This is in line with Guerrero et al. [31] and Stahlmann et al. [32] who reported that a third of CDI-positive patients would have been missed using toxin EIA compared to PCR. This is important, as patients with EIA-negative results did not differ in clinical presentation from EIA-positive patients and posed a significant risk for transmission [29] . Considering that around 25% of CDI patients were suggested to be infected by ward-based patient-to-patient transmission [33, 34] , the clinical and financial impact of misidentification of CDI cases would be important. In laboratories using a two-step GDH/toxin EIA algorithm, costs incurred due to repeat testing performed when the GDH result alone is positive, increased use of antibiotics for those patients with GDH positives which do not confirm with EIA and the increased length of time to a positive toxin result have to be considered. In our clinical study, 35.2% of patients with GDH-positive specimens did not clinically present CDI [17] . Retesting, treating and isolating patients with false-positive results wastes resources. We observed that GDH failed to pick up a case of CDI, part of a ward outbreak, which was presumptive C. difficile ribotype 027 positive with PCR and two GDH-positive 027 cases tested negative by toxin EIA.
The diagnostic accuracy of PCR methods has been established in several trials [11, 15, 28, 29, 35] . However, additional positives identified by PCR are often described as false positives when results are only compared to other assays in the laboratory setting and clinical presentation is not considered [36] . Our clinical study showed that out of 59 discrepant samples (CCNA negative but PCR positive), 54 (91.5%) were found to be true positives on clinical diagnosis which demonstrates convincingly that PCR results are reliable and accurate for diagnosing CDI, at the same time reducing the need for repeat testing. This was confirmed by Napierala et al. [37] who found that after implementation of PCR, testing volume as well as CDI rates decreased significantly. Increased faith of clinicians in a more accurate testing method not only impacts on CDI-positive patients but also affects CDI-negative patients, who can be assessed for other gastrointestinal problems at an earlier point in time without having to revisit CDI as a cause for diarrhea. Other patients can be discharged without further C. difficile testing due to the accurate negative results. This was reflected in our study by an average earlier discharge of 7.03 days for PCR-negative patients when compared to matched CCNA control patients. Similar results were reported by Grein et al. [38] who found that average CDI treatment days for negative patients and LOS after CDI diagnosis were shorter with PCR testing compared to toxin EIA and two-step testing.
GDH/toxin EIA results were not reported and thus not used for patient management.
Therefore, no direct cost comparison of the GDH followed by toxin EIA algorithm with CCNA and PCR could be performed, which might be considered a limitation of the study.
CCNA was used as a reference method as it was the routine test for C. difficile detection in the two hospitals at the time of data collection.
While it could be criticized that CCNA is not an optimal reference due to its high turnaround time and technical requirements, it has since been shown to correlate well with clinical diagnosis [39] . Our clinical study found a sensitivity and specificity of 99.1% and 98.9% for PCR and 51% and 99.4% for CCNA, respectively, compared to clinical diagnosis [17] . PCR testing produced 1 false negative and 10 false positives in 1,034 patients compared to CCNA which generated 55 false negatives and 5 false positives. These misidentifications will result in additional resource use and cost due to unnecessary treatment for false positives and repeat testing and increased risk of transmission and spread of infection for false negatives. Whereas repeat testing due to false negative CCNA results was accounted for in the calculations (Appendix 1 in the ESM), additional treatment costs were not considered in this study which could underestimate the cost saving potential of PCR due to the high number of false negatives by CCNA and the generally higher accuracy of PCR testing [15] . Our study was conducted in two acute hospitals in one trust in Wales and calculations and results are based on figures specific for ABMUHB. While this could limit generalizability of the results, cost savings generated by PCR testing were relatively insensitive to changes in sample quantity, CDI incidence and discount rates on material and consumables required for testing and can therefore be applied to various different laboratory settings in the UK. Even though the sample size of this study was large compared to other studies on CDI, the lack of significance in the LOS differences between the study groups is a major limitation of this study which could be addressed by future studies adequately powered to overcome the large variances in patient LOS observed in our study. Future research should also take into account potential longer term consequences such as CDI recurrences.
CONCLUSION
The routine use of a rapid molecular test for C.
difficile in an acute hospital setting produced quick results that led to a decrease in LOS compared to CCNA control patients. While LOS differences were not statistically significant in this study and costs of PCR testing are higher than costs of CCNA per sample, rapid molecular tests can realize potentially large cost savings due to the reduction of excess inpatient days and reduction in cost per total patient care episode. difficile care pathway for clinical diagnosis and management, and no additional specimens were collected for study purposes.
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